Omalizumab was effective for pediatric patients with recalcitrant chronic spontaneous urticaria (CSU), according to the findings of a recent study.
In the retrospective, multicenter case series, 19 patients with recalcitrant CSU between ages 6 and 16.9 years from five tertiary care centers in Israel were treated with omalizumab. The researchers used electronic medical records to gather data and follow patients throughout the duration of omalizumab therapy and symptom remission.
The researchers found 16 (84%) patients responded to omalizumab, including children less than 12 years. However, two patients became nonresponsive after 6 to 12 months of therapy. In addition, three patients (16%) were resistant to treatment and only achieved remission after initiating another fourth-line therapy.
“Children with recalcitrant CSU, even those less than 12 years old, respond well to standard‐dose, third‐line omalizumab therapy at rates similar to adults. Yet, some cases may become non‐responsive with ongoing treatment,” the researchers concluded.
Ari A, Levy Y, Segal N, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: a multi-center retrospective case series. Pediatr Dermatol. Published online September 19, 2020. doi:10.1111/pde.14360